Synlogic reports first quarter 2023 financial results and provides business update

- phenylketonuria (pku) program on track for phase 3 trial initiation in first half of 2023 – - recent milestones include receipt of rare pediatric and orphan drug designations from the fda, and orphan designation from the ema for synb1934 as a potential treatment for pku - cambridge, mass., may 11, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the first quarter ended march 31, 2023, and provided an update on its pipeline programs.
SYBX Ratings Summary
SYBX Quant Ranking